XERSXeris Biopharma Holdings, Inc.
Is the price fair?
Rich vs its sector. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What XERS's price assumes
Xeris Biopharma Holdings, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 3.81× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 4.20
EV / sales
Details›
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 38.5
- EV / salestoday's price, trailing year to Jun 30, 2026
- 4.20
- Market capitalisation
- $1.28B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #25 of 41 by RyuScore